Could Proteostasis Therapeutics Inc (NASDAQ:PTI) Change Direction After Less Shorts?

August 10, 2018 - By Eugene Smith

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Logo

The stock of Proteostasis Therapeutics Inc (NASDAQ:PTI) registered a decrease of 14.58% in short interest. PTI’s total short interest was 2.24 million shares in August as published by FINRA. Its down 14.58% from 2.62M shares, reported previously. With 538,900 shares average volume, it will take short sellers 4 days to cover their PTI’s short positions. The short interest to Proteostasis Therapeutics Inc’s float is 15.42%.

The stock decreased 2.45% or $0.06 during the last trading session, reaching $2.39. About 107,709 shares traded. Proteostasis Therapeutics, Inc. (NASDAQ:PTI) has risen 10.56% since August 10, 2017 and is uptrending. It has underperformed by 2.01% the S&P500.

Proteostasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics that treat diseases caused by dysfunctional protein processing, such as cystic fibrosis. The company has market cap of $86.23 million. The Company’s lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class that is in Phase-I studies. It currently has negative earnings. The firm is also developing PTI-801, a corrector molecule; PTI-808, a potentiator molecule; and unfolded protein response modulators that are in preclinical development.

Another recent and important Proteostasis Therapeutics, Inc. (NASDAQ:PTI) news was published by Bizjournals.com which published an article titled: “Apartment complex near Boston Landing sells for $43M” on August 06, 2018.

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: